**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

**Claims 1 to 45. (canceled)**

**Claim 46. (currently amended)** A compound of formula (I):




(I)

wherein $R^1$ represents a $C_1$-$C_6$ alkyl group, an amino group, a ($C_1$-$C_6$ alkyl) amino group, a di($C_1$-$C_6$ alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

$R^2$ and $R^3$ are the same or different and represent a hydrogen atom or a $C_1$-$C_6$ alkyl group;

Arom represents an unsubstituted ~~aryl~~ phenyl group[[, an]] ~~aryl~~ or a phenyl group substituted at from 1 to 5 positions by one or more substituents which are the same or different and are from the substituent group α; ~~an unsubstituted heteroaryl group~~[[,]] ~~or a heteroaryl group substituted at from~~ [[1 to 3]] ~~positions by one or more substituents which are the same or different and are from a substituent group α~~;

A represents a $C_1$-$C_6$ alkylene group;

$R^a$ represents a hydrogen atom, a $C_1$-$C_6$ alkyl group or a $C_2$-$C_6$ alkenyl group [[or,]] ~~together with~~ [[$R^2$,]] ~~represents a~~ [[$C_1$-$C_3$]] ~~alkylene group without a double bond or a~~ [[$C_2$-$C_3$]] ~~alkylene group with a double bond~~;

E represents [[a]] ~~single bond~~[[,]] an oxygen atom, a sulfur atom or a group of the formula $-NR^4-$, wherein $R^4$ represents a hydrogen atom or a $C_1$-$C_7$ alkanoyl group;

$X^1$ ~~and~~ [[$X^2$]] ~~are the same or different and represent~~ represents an oxygen atom or a sulfur atom;

$X^2$ is oxygen and is attached at position C4 of the phenyl ring;

the substituent group α being selected from the group consisting of a halogen atom, $C_1$-$C_6$ alkyl group, halogeno $C_1$-$C_6$

alkyl group, $C_1$-$C_6$ alkoxy group, $C_1$-$C_6$ alkylthio group, $C_1$-$C_3$ alkylenedioxy group, $C_1$-$C_7$ alkanoyl group, $C_2$-$C_7$ alkyloxycarbonyl group, amino group, $C_1$-$C_7$ alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group;

or a pharmacologically acceptable salt or ester thereof.

**Claim 47. (currently amended)** A compound of formula (I):




(I)

wherein $R^1$ represents a $C_1$-$C_6$ alkyl group, an amino group, a ($C_1$-$C_6$ alkyl) amino group, a di($C_1$-$C_6$ alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

$R^2$ and $R^3$ are the same or different and represent a hydrogen atom or a $C_1$-$C_6$ alkyl group;

Arom represents an unsubstituted ~~aryl~~ phenyl group[[, an]] ~~aryl~~ or a phenyl group substituted at from 1 to 5 positions by one or more substituents which are the same or different and are

from the substituent group α; ~~an unsubstituted heteroaryl group~~[[,]] ~~or a heteroaryl group substituted at from~~ [[1 to 3]] ~~positions by one or more substituents which are the same or different and are from a substituent group α~~;

A represents a $C_1$-$C_6$ alkylene group;

$R^a$ represents a hydrogen atom, a $C_1$-$C_6$ alkyl group or a $C_2$-$C_6$ alkenyl group [[or,]] ~~together with~~ [[$R^2$,]] ~~represents a~~ [[$C_1$-$C_3$]] ~~alkylene group without a double bond or a~~ [[$C_2$-$C_3$]] ~~alkylene group with a double bond~~;

E represents [[a]] ~~single bond~~[[,]] an oxygen atom, a sulfur atom or a group of the formula $-NR^4-$, wherein $R^4$ represents a hydrogen atom or a $C_1$-$C_7$ alkanoyl group;

$X^1$ ~~and~~ [[$X^2$]] ~~are the same or different and represent~~ represents an oxygen atom or a sulfur atom;

$X^2$ is oxygen and is attached at position C4 of the phenyl ring;

wherein the group of formula $R^1$-C(=$X^1$)- is a ($C_1$-$C_4$ alkyl) carbamoyl group or a di($C_1$-$C_4$ alkyl) carbamoyl group;

the substituent group α being selected from the group consisting of a halogen atom, $C_1$-$C_6$ alkyl group, halogeno $C_1$-$C_6$ alkyl group, $C_1$-$C_6$ alkoxy group, $C_1$-$C_6$ alkylthio group, $C_1$-$C_3$

alkylenedioxy group, $C_1$-$C_7$ alkanoyl group, $C_2$-$C_7$ alkyloxycarbonyl group, amino group, $C_1$-$C_7$ alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group;

or a pharmacologically acceptable salt or ester thereof.

**Claim 48. (currently amended)** A compound of formula (I):




(I)

wherein **[[**$R^1$**]]** ~~represents a~~ **[[**$C_1$-$C_6$**]]** ~~alkyl group~~**[[,]]** ~~an amino group~~**[[,]]** ~~a (~~**[[**$C_1$-$C_6$**]]** ~~alkyl) amino group~~**[[,]]** ~~a di(~~**[[**$C_1$-$C_6$**]]** ~~alkyl) amino group or a nitrogen~~**[[-]]**~~containing saturated heterocyclic group~~**[[;]]**

$R^2$ and $R^3$ are the same or different and represent a hydrogen atom or a $C_1$-$C_6$ alkyl group;

Arom represents an unsubstituted ~~aryl~~ phenyl group**[[**, an**]]** ~~aryl~~ or a phenyl group substituted at from 1 to 5 positions by one or more substituents which are the same or different and are from the substituent group α; ~~an unsubstituted heteroaryl~~

~~group~~[[,]] ~~or a heteroaryl group substituted at from~~ [[1 to 3]] ~~positions by one or more substituents which are the same or different and are from a substituent group α;~~

A represents a $C_1$-$C_6$ alkylene group;

$R^a$ represents a hydrogen atom, a $C_1$-$C_6$ alkyl group or a $C_2$-$C_6$ alkenyl group [[or,]] ~~together with~~ [[$R^2$,]] ~~represents a~~ [[$C_1$-$C_3$]] ~~alkylene group without a double bond or a~~ [[$C_2$-$C_3$]] ~~alkylene group with a double bond~~;

E represents [[a]] ~~single bond~~[[,]] an oxygen atom, a sulfur atom or a group of the formula $-NR^4-$, wherein $R^4$ represents a hydrogen atom or a $C_1$-$C_7$ alkanoyl group;

[[$X^1$]] ~~and~~ [[$X^2$]] ~~are the same or different and represent an oxygen atom or a sulfur atom~~[[;]]

$X^2$ is oxygen and is attached at position C4 of the phenyl ring;

wherein the group of formula $R^1$-C(=$X^1$)- is a dimethylcarbamoyl group or an ethylmethylcarbamoyl group;

the substituent group α being selected from the group consisting of a halogen atom, $C_1$-$C_6$ alkyl group, halogeno $C_1$-$C_6$ alkyl group, $C_1$-$C_6$ alkoxy group, $C_1$-$C_6$ alkylthio group, $C_1$-$C_3$ alkylenedioxy group, $C_1$-$C_7$ alkanoyl group, $C_2$-$C_7$ alkyloxycarbonyl

group, amino group, $C_1$-$C_7$ alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group; or a pharmacologically acceptable salt or ester thereof.

**Claim 49. (currently amended)** A compound of formula (I):




(I)

wherein $R^1$ represents a $C_1$-$C_6$ alkyl group, an amino group, a ($C_1$-$C_6$ alkyl) amino group, a di($C_1$-$C_6$ alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

$R^2$ and $R^3$ are the same or different and represent a hydrogen atom or a $C_1$-$C_6$ alkyl group;

Arom is a phenyl group substituted at one or two positions by one or more substituents which are the same or different and are from a substituent group α1, or a phenyl group substituted at three positions by halogen atoms;

A represents a $C_1$-$C_6$ alkylene group;

$R^a$ represents a hydrogen atom, a $C_1$-$C_6$ alkyl group or a $C_2$-$C_6$ alkenyl group [[or,]] ~~together with~~ [[$R^2$,]] ~~represents a~~ [[$C_1$-$C_3$]] ~~alkylene group without a double bond or a~~ [[$C_2$-$C_3$]] ~~alkylene group with a double bond~~;

E represents [[a]] ~~single bond~~[[,]] an oxygen atom, a sulfur atom or a group of the formula $-NR^4-$, wherein $R^4$ represents a hydrogen atom or a $C_1$-$C_7$ alkanoyl group;

$X^1$ [[and $X^2$]] ~~are the same or different and represent~~ represents an oxygen atom or a sulfur atom;

$X^2$ is oxygen and is attached at position C4 of the phenyl ring;

the substituent group αl being selected from the group consisting of a halogen atom, unsubstituted $C_1$-$C_4$ alkyl group, $C_1$-$C_4$ alkyl group substituted by from 1 to 3 fluorine atoms, $C_1$-$C_4$ alkoxy group, $C_1$-$C_4$ alkylthio group, methylenedioxy group, ethylenedioxy group, $C_1$-$C_4$ alkanoyl group, cyano group and nitro group;

or a pharmacologically acceptable salt or ester thereof.

**Claim 50. (currently amended)** A compound of formula (I):




(I)

wherein $R^1$ represents a $C_1$-$C_6$ alkyl group, an amino group, a ($C_1$-$C_6$ alkyl) amino group, a di($C_1$-$C_6$ alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

$R^2$ and $R^3$ are the same or different and represent a hydrogen atom or a $C_1$-$C_6$ alkyl group;

Arom is a phenyl group substituted at one or two positions by one or more substituents which are the same or different and are from a substituent group α3, or a phenyl group substituted at three positions by fluorine atoms;

A represents a $C_1$-$C_6$ alkylene group;

$R^a$ represents a hydrogen atom, a $C_1$-$C_6$ alkyl group or a $C_2$-$C_6$ alkenyl group **[[**or,**]]** ~~together with~~ **[[**$R^2$,**]]** ~~represents a~~ **[[**$C_1$-$C_3$**]]** ~~alkylene group without a double bond or a~~ **[[**$C_2$-$C_3$**]]** ~~alkylene group with a double bond~~;

E represents **[[**a**]]** ~~single bond~~**[[**,**]]** an oxygen atom, a sulfur atom or a group of the formula $-NR^4-$, wherein $R^4$ represents a hydrogen atom or a $C_1$-$C_7$ alkanoyl group;

$X^1$ ~~and~~ **[[**$X^2$**]]** ~~are the same or different and represent~~ represents an oxygen atom or a sulfur atom;

$X^2$ is oxygen and is attached at position C4 of the phenyl ring;

the substituent group α3 being selected from the group consisting of a fluorine atom, chlorine atom, methylthio group, acetyl group, cyano group and nitro group;

or a pharmacologically acceptable salt or ester thereof.

**Claim 51. (previously presented)** A compound of formula (I):




(I)

wherein $R^1$ represents a $C_1$-$C_6$ alkyl group, an amino group, a ($C_1$-$C_6$ alkyl) amino group, a di($C_1$-$C_6$ alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

$R^2$ and $R^3$ are the same or different and represent a hydrogen atom or a $C_1$-$C_6$ alkyl group;

Arom is a phenyl group substituted at one position by a fluorine atom, a chlorine atomor a nitro group, or a phenyl group substituted at two positions by fluorine atoms;

A represents a $C_1$-$C_6$ alkylene group;

$R^a$ represents a hydrogen atom, a $C_1$-$C_6$ alkyl group or a $C_2$-$C_6$ alkenyl group **[[**or,**]]** ~~together with~~ **[[**$R^2$,**]]** ~~represents a~~ **[[**$C_1$-$C_3$**]]** ~~alkylene group without a double bond or a~~ **[[**$C_2$-$C_3$**]]** ~~alkylene group with a double bond~~;

E represents **[[**a**]]** ~~single bond~~**[[**,**]]** an oxygen atom, a sulfur atom or a group of the formula -$NR^4$-, wherein $R^4$ represents a hydrogen atom or a $C_1$-$C_7$ alkanoyl group;

$X^1$ ~~and~~ **[[**$X^2$**]]** ~~are the same or different and represent~~ represents an oxygen atom or a sulfur atom;

$X^2$ is oxygen and is attached at position C4 of the phenyl ring;

or a pharmacologically acceptable salt or ester thereof.

**Claim 52. (previously presented)** A compound of formula (I):




(I)

wherein $R^1$ represents a $C_1$-$C_6$ alkyl group, an amino group, a ($C_1$-$C_6$ alkyl) amino group, a di($C_1$-$C_6$ alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

$R^2$ and $R^3$ are the same or different and represent a hydrogen atom or a $C_1$-$C_6$ alkyl group;

Arom is a 4-fluorophenyl group, a 4-chlorophenyl group, a 4-nitrophenyl group or a 3,4-difluorophenyl group;

A represents a $C_1$-$C_6$ alkylene group;

$R^a$ represents a hydrogen atom, a $C_1$-$C_6$ alkyl group or a $C_2$-$C_6$ alkenyl group **[[**or,**]]** ~~together with~~ **[[**$R^2$,**]]** ~~represents a~~ **[[**$C_1$-$C_3$**]]** ~~alkylene group without a double bond or a~~ **[[**$C_2$-$C_3$**]]** ~~alkylene group with a double bond~~**[[**;**]]**

E represents **[[**a**]]** ~~single bond~~**[[**,**]]** an oxygen atom, a sulfur atom or a group of the formula $-NR^4-$, wherein $R^4$ represents a

hydrogen atom or a $C_1$-$C_7$ alkanoyl group;

$X^1$ ~~and~~ [[$X^2$]] ~~are the same or different and represent~~ represents an oxygen atom or a sulfur atom;

$X^2$ is oxygen and is attached at position C4 of the phenyl ring;

or a pharmacologically acceptable salt or ester thereof.

**Claim 53. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein the group of formula: $R^1$-C (=$X^1$)- is a carbamoyl group, a ($C_1$-$C_4$ alkyl) carbamoyl group, a di($C_1$-$C_4$ alkyl)carbamoyl group, a thiocarbamoyl group, a ($C_1$-$C_4$ alkyl) thiocarbamoyl group or a di($C_1$-$C_4$ alkyl) thiocarbamoyl group.

**Claim 54. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein the group of formula $R^1$-C(=$X^1$)- is a ($C_1$-$C_4$ alkyl) carbamoyl group, a di($C_1$-$C_4$ alkyl)carbamoyl group, a ($C_1$-$C_4$ alkyl) thiocarbamoyl group or a di($C_1$-$C_4$ alkyl)thiocarbamoyl group.

**Claim 55. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein the group of formula $R^1$-C(=$X^1$)- is a di($C_1$-$C_4$ alkyl)carbamoyl group.

**Claim 56. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein the group of formula $R^1$-C(=$X^1$)- is a dimethylcarbamoyl group.

**Claim 57. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein $R^3$ is a $C_1$-$C_6$ alkyl group.

**Claim 58. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein $R^3$ is a methyl group or an ethyl group.

**Claim 59. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to

any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein $R^3$ is a methyl group.

**Claim 60. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein $R^2$ is a hydrogen atom or a $C_1$-$C_6$ alkyl group.

**Claim 61. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein $R^2$ is a hydrogen atom, a methyl group or an ethyl group.

**Claim 62. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein $R^2$ is a hydrogen atom or a methyl group.

**Claim 63. (canceled)**

**Claim 64. (canceled)**

**Claim 65. (canceled)**

**Claim 66. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein $R^a$ is a hydrogen atom or a methyl group.

**Claim 67. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein $R^a$ is a hydrogen atom.

**Claim 68. (currently amended)** The compound or pharmacologically acceptable salt or ester thereof according to Claims 46 or 47, wherein Arom is ~~an unsubstituted phenyl group~~**[[,]]** a phenyl group substituted at from 1 to 3 positions by one or more substituents which are the same or different and are from the substituent group α, ~~an unsubstituted pyridyl group~~**[[,]]** ~~or a pyridyl group substituted at one position by a substituent from the substituent group~~ **[[α]]**,

the substituent group α being selected from the group consisting of a halogen atom, $C_1$-$C_6$ alkyl group, halogeno $C_1$-$C_6$ alkyl group, $C_1$-$C_6$ alkoxy group, $C_1$-$C_6$ alkylthio group, $C_1$-$C_3$ alkylenedioxy group, $C_1$-$C_7$ alkanoyl group, $C_2$-$C_7$ alkyloxycarbonyl group, amino group, $C_1$-$C_7$ alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group.

**Claim 69. (canceled)**

**Claim 70. (previously presented)** The compound or pharmacologically acceptable salt thereof according to Claims 46 or 47, wherein Arom is a phenyl group substituted at one or two positions by substituent(s) which are the same or different and are from a substituent group α2, or a phenyl group substituted at three positions by fluorine atoms or chlorine atoms; substituent group α2 being selected from the group consisting of a fluorine atom, chlorine atom, methyl group, trifluoromethyl group, methoxy group, methylthio group, acetyl group, cyano group and nitro group.

**Claim 71. (previously presented)** The compound or pharmacologically acceptable salt thereof according to Claims 46

or 47, wherein Arom is a phenyl group substituted at one or two positions by one or more substituents which are the same or different and are from a substituent group α4, or a phenyl group substituted at three positions by fluorine atoms;
substituent group α4 being selected from the group consisting of a fluorine atom, chlorine atom, methylthio group and nitro group.

**Claim 72. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein A is a $C_1$-$C_4$ alkylene group.

**Claim 73. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein A is a methylene group or an ethylene group.

**Claim 74. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein A is an ethylene group.

**Claim 75. (canceled)**

**Claim 76. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein E is an oxygen atom.

**Claim 77. (canceled)**

**Claim 78. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein the group of formula $R^1$-C(=$X^1$)-$X^2$- is attached at the para-position.

**Claim 79. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein $R^1$ is an amino group, a ($C_1$-$C_6$ alkyl)amino group or a di($C_1$-$C_6$ alkyl)amino group.

**Claim 80. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein $R^1$ is an amino group, a ($C_1$-$C_4$ alkyl)amino group or a di($C_1$-$C_4$ alkyl)amino group.

**Claim 81. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein $R^1$ is a ($C_1$-$C_4$ alkyl)amino group or a di($C_1$-$C_4$ alkyl)amino group.

**Claim 82. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein $X^1$ is an oxygen atom.

**Claim 83. (currently amended)** The compound or pharmacologically acceptable salt or ester thereof according to Claim 46, wherein the compound is 4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl ~~dimethcarbamate~~ dimethylcarbamate.

**Claim 84. (currently amended)** A compound of the formula (I):




(I)

wherein $R^1$ represents a $C_1$-$C_6$ alkyl group, an amino group, a ($C_1$-$C_6$ alkyl)amino group, a di($C_1$-$C_6$ alkyl)amino group or a nitrogen-containing saturated heterocyclic group;

$R^2$ and $R^3$ are the same or different and represent a hydrogen atom or a $C_1$-$C_6$ alkyl group;

Arom represents an unsubstituted ~~aryl~~ phenyl group[[, an]] ~~aryl~~ or a phenyl group substituted at from 1 to 3 positions by substituents, which are the same or different and are from a substituent group α; ~~an unsubstituted heteroaryl group~~[[,]] ~~or a heteroaryl group substituted at from 1 to 3 positions by one or more substituents which are the same or different and are from a substituent group α~~[[;]]

A represents a $C_1$-$C_6$ alkylene group;

E represents [[a]] ~~single bond~~[[,]] an oxygen atom, a sulfur atom or a group of the formula $-NR^4-$, wherein $R^4$ represents a hydrogen atom or a $C_1$-$C_7$ alkanoyl group;

$X^1$ ~~and~~ [[$X^2$]] ~~are the same or different and represent~~ represents an oxygen atom or a sulfur atom;

$X^2$ is oxygen and is attached at position C4 of the phenyl ring;

the substituent group α being selected from the group consisting of a halogen atom, $C_1$-$C_6$ alkyl group, halogeno $C_1$-$C_6$ alkyl group, $C_1$-$C_6$ alkoxy group, $C_1$-$C_6$ alkylthio group, $C_1$-$C_3$ alkylenedioxy group, $C_1$-$C_7$ alkanoyl group, $C_2$-$C_7$ alkyloxycarbonyl group, amino group, $C_1$-$C_7$ alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group;

or a pharmacologically acceptable salt or ester thereof.

**Claim 85. (previously presented)** A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 46, in combination with a pharmaceutically acceptable carrier.

**Claim 86. (previously presented)** A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 47, in combination with a pharmaceutically acceptable carrier.

**Claim 87. (previously presented)** A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 48, in combination with a pharmaceutically acceptable carrier.

**Claim 88. (previously presented)** A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 49, in combination with a pharmaceutically acceptable carrier.

**Claim 89. (previously presented)** A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 50, in combination with a pharmaceutically acceptable carrier.

**Claim 90. (previously presented)** A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to

Claim 51, in combination with a pharmaceutically acceptable carrier.

**Claim 91. (previously presented)** A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 52, in combination with a pharmaceutically acceptable carrier.

**Claim 92. (previously presented)** A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 83, in combination with a pharmaceutically acceptable carrier.

**Claims 93 to 101. (canceled)**

**Claim 102. (previously presented)** A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a mammal comprising administering to a mammal a pharmaceutically effective

amount of a compound or a pharmacologically acceptable salt or ester thereof according to Claim 46.

**Claim 103. (previously presented)** A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 46.

**Claim 104. (previously presented)** A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 47.

**Claim 105. (previously presented)** A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically

effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 48.

**Claim 106. (previously presented)** A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 49.

**Claim 107. (previously presented)** A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 50.

**Claim 108. (previously presented)** A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically

effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 51.

**Claim 109. (previously presented)** A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 52.

**Claim 110. (canceled)**

**Claim 111. (previously presented)** A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 46.

**Claim 112. (previously presented)** A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or

pharmacologically acceptable salt or ester thereof according to Claim 47.

**Claim 113. (previously presented)** A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 48.

**Claim 114. (previously presented)** A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 49.

**Claim 115. (previously presented)** A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 50.

**Claim 116. (previously presented)** A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 51.

**Claim 117. (previously presented)** A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 52.

**Claim 118. (canceled)**

**Claim 119. (previously presented)** The compound or pharmacologically acceptable salt or ester thereof according to Claim 46, wherein $R^1$ is a dimethylamino group, $X^1$ and $X^2$ are both oxygen, Ra is H, $R^2$ is hydrogen, $R^3$ is methyl, A is $-C_2H_4$, E is oxygen and Arom is a phenyl group substituted in the 4-position by a $NO_2$ group.

**Claim 120. (new)** The compound according to claim 46, wherein the compound is selected from the group consisting of

4-[3-(4-fluorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
4-[3-(3-fluorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
4-[3-(4-chlorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
4-[3-(3-chlorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
4-[3-(3,4-difluorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
4-[3-(4-chloro-3-fluorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
4-[3-(2-chloro-4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
4-[1-dimethylamino-3-(4-fluorophenoxy)propyl]phenyl dimethylcarbamate,
4-[1-dimethylamino-3-(3-fluorophenoxy)propyl]phenyl dimethylcarbamate,
4-[3-(4-chlorophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,
4-[3-(3-chlorophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,

4-[3-(4-cyanophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,
4-[1-dimethylamino-3-(4-nitrophenoxy)propyl]phenyl dimethylcarbamate,
4-[3-(3,4-difluorophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,
4-[3-(2-chloro-4-nitrophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,
4-[3-(4-nitrophenylsulfanyl)-1-methylaminopropyl]phenyl dimethylcarbamate,
4-(1-methylamino-3-p-toluyloxypropyl)phenyl dimethylcarbamate hydrochloride,
4-[1-methylamino-3-[(4-trifluoromethyl)phenoxy]propyl]phenyl dimethylcarbamate,
4-[3-(4-cyanophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate and
4-[1-methylamino-3-(3-nitrophenoxy)propyl]phenyl dimethylcarbamate
or a pharmacologically acceptable salt or ester thereof.

**Claim 121. (new)** The compound according to claim 46, wherein the compound is 4-[3-(4-chlorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate or a pharmacologically acceptable salt or ester thereof.

**Claim 122. (new)** The compound according to claim 46, wherein the compound is (S)-4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate or a pharmacologically acceptable salt or ester thereof.

**Claim 123. (new)** The compound according to claim 46, wherein the compound is (S)-4-[3-(4-chlorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate or a pharmacologically acceptable salt or ester thereof.

**Claim 124. (new)** The compound according to claim 46, wherein the compound is (S)-4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate hydrochloride.

**Claim 125. (new)** The compound according to claim 46, wherein the compound is (S)-4-[3-(4-chlorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate hydrochloride.

**Claim 126. (new)** The compound according to claim 46, wherein the compound is (S)-4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate hemifumarate.

**Claim 127. (new)** The compound according to claim 46, wherein the compound is (S)-4-[3-(4-chlorophenoxy)-1-methylaminopropyl] phenyl dimethylcarbamate hemifumarate.

**Claim 128. (new)** A method of treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically acceptable amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 83, 121, 122 or 123.

**Claim 129. (new)** A method of treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically acceptable amount of a compound according to any one of claims 124, 125, 126 or 127.

**Claim 130. (new)** A method of treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically acceptable amount of a compound according to claim 126.

**Claim 131. (new)** A method of treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically acceptable amount of a compound or pharmaceutically acceptable salt thereof according to any one of claims 83, 121, 122 or 123.

**Claim 132. (new)** A method of treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically acceptable amount of a compound according to any one of claims 124, 125, 126 or 127.

**Claim 133. (new)** A method of treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically acceptable amount of a compound or pharmaceutically acceptable salt thereof according to claim 126.